Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP
1997

Evaluating the Effectiveness of 8-Chloro-cAMP in Cancer Treatment

Sample size: 107 publication Evidence: moderate

Author Information

Author(s): AG Bosanquet, AR Buriton, PB Bell, AL Harris

Primary Institution: Bath Cancer Research Unit, University of Bath

Hypothesis

Can the DiSC assay effectively identify clinically active agents like 8-chloro-cAMP in cancer treatment?

Conclusion

The study found that 8-chloro-cAMP shows significant cytotoxic activity against certain types of leukemia and lymphoma, suggesting its potential as a new cancer treatment.

Supporting Evidence

  • 8-chloro-cAMP showed significant ex vivo activity against chronic lymphocytic leukaemia (CLL) with a mean LC90 of 117.0 µM.
  • 8-chloro-cAMP demonstrated significant cytotoxicity against non-Hodgkin's lymphoma (NHL) with a mean LC90 of 140.0 µM.
  • The drug was particularly effective against acute myeloid leukaemia (AML) with a mean LC90 of 24.3 µM.
  • Minimal cross-resistance with other cytotoxic drugs was detected.
  • Patients previously treated for CLL showed no increase in resistance to 8-chloro-cAMP.

Takeaway

Researchers tested a new drug called 8-chloro-cAMP on cancer cells and found it can kill some cancer cells better than normal cells, which is a good sign for treating cancer.

Methodology

The DiSC assay was used to assess the cytotoxicity of 8-chloro-cAMP on fresh human neoplastic and normal cells.

Limitations

The study primarily focused on specific cancer types and may not generalize to all cancers.

Participant Demographics

The study included patients with various types of leukemia and lymphoma, with a median age of 63.5 years.

Statistical Information

P-Value

0.878

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication